Atlas company financials

Kymera Therapeutics, Inc.

Standardized 7-year financial series for Kymera Therapeutics, Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001815442FY2019 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$39.2M

Adjusted EBITDA

—

Net result

-$311.4M

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$2.8M

TTM revenue

$40.1M

TTM free cash flow

—

Latest quarter net result

-$82.2M

Quarterly coverage: 19 periods · latest quarter FY2025-Q3 · TTM revenue growth -29.9%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · kymera-therapeutics-inc-fy2019 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2021-03-11 · Retrieved: 2026-04-26T11:50:41.918506+00:00
SEC EDGAR companyfacts
us-gaap:EarningsPerShareBasic · us gaap companyfacts · comparative · kymera-therapeutics-inc-fy2020 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2023-02-23 · Retrieved: 2026-04-26T11:50:41.918506+00:00
SEC EDGAR companyfacts
primary · kymera-therapeutics-inc-fy2021 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2022-02-24 · Retrieved: 2026-04-26T11:50:41.918506+00:00
SEC EDGAR companyfacts
us-gaap:CostOfRevenue · us gaap companyfacts · comparative · kymera-therapeutics-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2025-02-27 · Retrieved: 2026-04-26T11:50:41.918506+00:00
SEC EDGAR companyfacts
us-gaap:AccountsReceivableNetCurrent · us gaap companyfacts · comparative · kymera-therapeutics-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2024-02-22 · Retrieved: 2026-04-26T11:50:41.918506+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2019	3M	—	-42M	-41M	18M	-532K	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing basic eps · missing cost of revenue · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2020	34M	—	-46M	-46M	88M	-9M	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2021	73M	—	-101M	-100M	-129M	-2M	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2022	47M	—	-161M	-155M	-153M	-3M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2023	79M	—	-166M	-147M	-103M	-34M	—	missing adjusted ebitda · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2024	47M	—	-262M	-224M	-195M	-13M	—	missing adjusted ebitda · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2025	39M	—	-349M	-311M	-233M	-1M

Filing provenance